Literature DB >> 33859324

4-Methylumbelliferone administration enhances radiosensitivity of human fibrosarcoma by intercellular communication.

Ryo Saga1, Yusuke Matsuya2,3, Rei Takahashi4, Kazuki Hasegawa4, Hiroyuki Date3, Yoichiro Hosokawa4.   

Abstract

Hyaluronan synthesis inhibitor 4-methylumbelliferone (4-MU) is a candidate of radiosensitizers which enables both anti-tumour and anti-metastasis effects in X-ray therapy. The curative effects under such 4-MU administration have been investigated in vitro; however, the radiosensitizing mechanisms remain unclear. Here, we investigated the radiosensitizing effects under 4-MU treatment from cell experiments and model estimations. We generated experimental surviving fractions of human fibrosarcoma cells (HT1080) after 4-MU treatment combined with X-ray irradiation. Meanwhilst, we also modelled the pharmacological effects of 4-MU treatment and theoretically analyzed the synergetic effects between 4-MU treatment and X-ray irradiation. The results show that the enhancement of cell killing by 4-MU treatment is the greatest in the intermediate dose range of around 4 Gy, which can be reproduced by considering intercellular communication (so called non-targeted effects) through the model analysis. As supposed to be the involvement of intercellular communication in radiosensitization, the oxidative stress level associated with reactive oxygen species (ROS), which leads to DNA damage induction, is significantly higher by the combination of 4-MU treatment and irradiation than only by X-ray irradiation, and the radiosensitization by 4-MU can be suppressed by the ROS inhibitors. These findings suggest that the synergetic effects between 4-MU treatment and irradiation are predominantly attributed to intercellular communication and provide more efficient tumour control than conventional X-ray therapy.

Entities:  

Year:  2021        PMID: 33859324     DOI: 10.1038/s41598-021-87850-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  45 in total

1.  Biological basis for chemo-radiotherapy interactions.

Authors:  C Hennequin; V Favaudon
Journal:  Eur J Cancer       Date:  2002-01       Impact factor: 9.162

Review 2.  Combination of chemotherapy and radiotherapy: A thirty years evolution.

Authors:  C Hennequin; S Guillerm; L Quero
Journal:  Cancer Radiother       Date:  2019-08-28       Impact factor: 1.018

3.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

4.  Anti-tumor and anti-invasion effects of a combination of 4-methylumbelliferone and ionizing radiation in human fibrosarcoma cells.

Authors:  Ryo Saga; Satoru Monzen; Mitsuru Chiba; Hironori Yoshino; Toshiya Nakamura; Yoichiro Hosokawa
Journal:  Oncol Lett       Date:  2016-11-15       Impact factor: 2.967

Review 5.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

6.  Synergy between Auraptene, Ionizing Radiation, and Anticancer Drugs in Colon Adenocarcinoma Cells.

Authors:  Mahdi Moussavi; Farhang Haddad; Fatemeh B Rassouli; Mehrdad Iranshahi; Shokouhozaman Soleymanifard
Journal:  Phytother Res       Date:  2017-07-04       Impact factor: 5.878

Review 7.  Distant metastatic spread of molecularly proven infantile fibrosarcoma of the chest in a 2-month-old girl: case report and review of literature.

Authors:  Martine van Grotel; Esther Blanco; Neil J Sebire; Olga Slater; Tanzina Chowdhury; John Anderson
Journal:  J Pediatr Hematol Oncol       Date:  2014-04       Impact factor: 1.289

Review 8.  Time and Demand are Two Critical Dimensions of Immunometabolism: The Process of Macrophage Activation and the Pentose Phosphate Pathway.

Authors:  Csörsz Nagy; Arvand Haschemi
Journal:  Front Immunol       Date:  2015-04-08       Impact factor: 7.561

9.  Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin.

Authors:  Chen-Hsi Hsieh; Mei-Ling Hou; Meng-Hsuan Chiang; Hung-Chi Tai; Hui-Ju Tien; Li-Ying Wang; Tung-Hu Tsai; Yu-Jen Chen
Journal:  J Transl Med       Date:  2013-09-26       Impact factor: 5.531

10.  Fibrosarcoma of maxilla: A rare case report.

Authors:  Sandhya Shrivastava; Sushruth K Nayak; Prachi Nayak; Sourabh Sahu
Journal:  J Oral Maxillofac Pathol       Date:  2016 Jan-Apr
View more
  1 in total

1.  Anti-Inflammatory and Mineralization Effects of an ASP/PLGA-ASP/ACP/PLLA-PLGA Composite Membrane as a Dental Pulp Capping Agent.

Authors:  Wenjuan Yan; Fenghe Yang; Zhongning Liu; Quan Wen; Yike Gao; Xufeng Niu; Yuming Zhao
Journal:  J Funct Biomater       Date:  2022-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.